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Abstract
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With an increase of resistance in bacteria there is an urgent need for alternative treatment methods
that could complement conventional antibiotics. In the past two decades, focus has been drawn to
Host Defense Peptides (HDPs) as potential antibiotic agents. Herein we reported our studies on the
development of lipidated α/α-AA heterogeneous peptides as a new class of HDP mimetics. These
compounds showed potent antimicrobial activity toward both Gram-positive and Gram-negative
bacteria, and they also displayed excellent selectivity as they only exhibited limited hemolytic
activity. The fluorescence microscopy suggested that the mechanism of action of these
heterogeneous peptides is bacterial membrane disruption, which is believed to be the major reason
why it is difficult for bacteria to develop resistance. The subsequent time kill studies suggested
that these compounds could rapidly eradicate bacteria. Moreover, this class of compounds could
also effectively clear biofilms formed by both Gram-positive and Gram-negative bacteria. These
findings suggested that lipidated α/α-AA heterogeneous peptides, as a new class of
peptidomimetics, are promising antibiotic agents combating antibiotic resistance.
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1. INTRODUCTION
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Bacterial infections have been the cause of many diseases that could lead to severe
conditions including death. For the past seventy years, antibiotics have been used to treat a
wide range of bacterial infections. However, due to the prolonged use and frequent misuse of
these conventional drugs, many microbes have become resistant to treatment. This problem
has led to the loss of effectiveness in the antibiotics to treat infections, resulting in a global
health concern.[1,2] Per the Center of Disease Control (CDC), over two million people
become infected with antibiotic resistant bacteria every year and of these approximately
twenty three thousand die.[3] The World Health Organization (WHO) also reports that
microbes are developing new mechanisms of resistance globally and this has caused a threat
in the ability to treat common diseases hence leading to prolonged illness, disability, and
death.[4] There is an urgent need to search for the alternative approaches combating the
emergent resistance in bacteria.
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Host Defense Peptides (HDPs), such as cathelicidin and definsins,[5,6] are natural
antimicrobial peptides which are produced in all classes of life. HDPs work by means of
either antimicrobial or by immunomodulatory functions, or both.[7,8] Briefly, they could
directly kill bacteria by compromising bacterial membranes.[9] Meanwhile, HDPs also
utilize their immunomodulatory functions to regulate the release of immune cells that affect
innate immunization against bacterial infections. For example, monocytes, lymphocytes and
granulocytes all activate immune cells to control the rate of inflammation and improve the
killing and removal of foreign bodies from the host after infection. [10–12] Although they
are diverse in their three-dimensional structures, HDPs generally are short cationic
sequences that make up of about no more than fifty amino acids and have both hydrophobic
and hydrophilic faces in their structures. Their positive charge allows for selectivity toward
bacteria which are all virtually negatively charged on their outer membrane leaflet, whereas
the hydrophobic patches of HDPs are critical for penetration and disruption of the bacterial
cell membranes.[13–15] Due to their low propensity to develop resistance as they lack
specific targets on the bacterial membranes, their high selectivity for bacterial cells over
mammalian cells, and their antimicrobial activity for a broad range of bacteria, significant
efforts have been devoted to the development of HDPs and their mimics.[16,17]
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Recently our group has designed a class of peptidomimetics termed α-AApeptides (Figure
1) whose backbone are derived from α chiral peptide nucleic acids (PNA).[18,19] The
design has been shown to be advantageous as it exhibits enhanced proteolytic stability,
bioavailability, and chemodiversity as the side chains can be diversified with a wide variety
of unnatural functional groups to allow design adapted to different circumstances. Our
previous studies show that α-AApeptides could be potential antimicrobial agents,[20] and
their activity could have improved antimicrobial activity upon adding a lipid tail to the
building block sequence.[21,22] We reasoned because adding a lipid tail to the sequence

Eur J Med Chem. Author manuscript; available in PMC 2019 July 15.

Singh et al.

Page 3

Author Manuscript

makes it more hydrophobic it increases its ability to interact with the lipid structures of the
bacterial cell membranes.[21] In addition, we recently show that hybrid peptides could be
potent and selective antimicrobial agents.[23] As such, it is envisioned that a new class of
lipidated hybrid peptides consisting of both α-AApeptide building blocks and canonical
amino acids could yield potent antibiotic agents with simple structures, and thereby more
promise of future development for practical use in therapeutics.

2. RESULTS AND DISCUSSION

Author Manuscript

These sequences were then tested for their antimicrobial activity against five reprehensive
strains (Table 1): Gram-negative bacteria Escherichia coli, K. pneumonia and Gram-positive
bacteria Methicillin resistant Staphylococcus aureus (MRSA), Methicillin Resistant S.
epidermidis, and Vancomycin resistant E. faecalis.[25,26] We first examined the activity of
sequences containing lysine residue, a lipid tail and one α-AA building block (n=1).
Interestingly, sequences containing C6, C8, C10 and C12 lipid tails did not shown any
activity under tested conditions. C14-K-BB1, bearing the C14 lipid tail, started to exhibit
weak activity against MRSA and E. Coli. With the longer C16 lipid tail, C16-K-BB1
displayed broad spectrum activity against all the tested Gram-positive and Gram-negative
strains. The results are indeed consistent to our previous findings that long lipid tails are
needed to endow sequences with sufficient hydrophobicity to penetrate lipid bilayers in
bacteria. However, to our surprise, C16-K-BB1 was highly hemolytic, probably due to its
high hydrophobic content.
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Building upon our previous findings[23], our design was aimed for molecular simplicity and
strong membrane reactivity. To this end, lysine residue was included to give an overall
positive charge, which is expected to attract the sequence to the surface of negatively
charged bacterial membranes. A lipid tail was employed to endow hydrophobicity,
facilitating sequence insertion into membranes. Furthermore, one or more amphiphilic αAApeptide building blocks containing a positively charged side chain and a hydrophobic
side chain were introduced to fine tune its membrane activity and selectivity (Scheme 1). All
the sequences were synthesized on the solid phase using standard solid phase peptide
synthesis (SPPS) protocol (Scheme 1. please see supporting information for details),[24] and
their structures are shown in Figure 2.

To obtain more potent antimicrobial agents with enhanced selectivity, we introduced more
α-AA building blocks (n=2, 3; m=15). Unfortunately, C16-K-BB2, only showed good
activity against MRSA and E. Coli, but not other stains. Meanwhile, it was still highly
hemolytic. However, it was intriguing that C16-K-BB3 showed excellent antimicrobial
activity towards all tested strains except for K. pneumoniae. In addition, it exhibited high
selectivity toward MRSA over mammalian cells. This demonstrated that proper ratio of
hydrophobic groups and positively charged groups could lead to potent and selective
antimicrobial α/α-AA hybrid. We next examined the impact of backbone on the
antimicrobial activity. As seen in Scheme 1 and Table 1, C16-BB1, which does not contain
the lysine residue, lost all the activity compared to C16-K-BB1. Whereas the other sequence
C16-K-F-K, bearing purely canonic amino acid residue but with similar hydrophobicity and
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hydrophilicity, also did not show any antimicrobial activity. The results suggested that α/αAA hybrid backbone are mandatory and unique for antimicrobial development.
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We then asked whether the position of the positive charge and the hydrophobic side chains
would influence the antimicrobial activity of the compounds. Thus, we synthesized another
three sequences bearing a C16 lipid tail, a lysine residue and one or more amphiphilic α-AA
building blocks with reversed side chains (Scheme 2) compared to structures in Figure 2.
Surprisingly, all three sequences exhibited broad-spectrum activity against both Grampositive and Gram-negative bacteria. Among them, C16-K-RBB1 is the most potent one
which showed excellent activity even toward K. pneumoniae whereas displayed limited cell
toxicity. Although C16-K-RBB2 was not active toward K. pneumoniae, its high selectivity
toward other bacterial strains including MRSA presents itself as a very promising
antimicrobial agent. Our results suggest that not only the ratio of hydrophobicity and
cationic charge is important for HDP mimetics, the three-dimensional distribution of
hydrophobic and cationic groups is also highly critical for bacterial killing. Therefore, based
on our above-mentioned findings, both C16-K-RBB1 and C16-K-RBB2 were chosen for the
subsequent mechanistic studies.
As C16-K-RBB2 having the best activity and selectivity toward E. coli and MRSA, we set
out to explore its mechanism of action to kill bacterial cells using fluorescence microscopy
(Figure 3). DAPI was used to stain both live and dead bacterial cells while PI was used to
stain the dead cells only.[27,28] Upon treatment of E. coli and MRSA with C16-K-RBB2 for
2 h, the bacterial cells showed red fluorescence in the PI channel, indicating that the
compound killed the bacterial cells by damaging their membranes.
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The Time kill assay was subsequently conducted using the most potent compound C16-KRBB1 to assess bacterial killing kinetics for this class of compounds. As shown in Figure
4A, it took 120 minutes for 12.5 μg/mL of C16-K-RBB1 to clear the bacteria E. Coli while it
just took 60 minutes for 25 μg/mL and 50 μg/mL C16-K-RBB1 to eradicate the bacteria. In
the case of MRSA (Figure 4B) the compound took 60 minutes for 12.5 μg/mL and 25 μg/mL
whereas only 10 minutes for 50 μg/mL to completely get rid of the bacteria. The results
demonstrated that the compounds could rapidly eradicate bacterial cells with bactericidal
function.
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One of the challenges faced when treating bacterial infections is their ability to develop
biofilm. Bacterial biofilms are formed by the ability of bacteria to irreversibly bind to a
surface and form a matrix that is made up of extra-polymer substances. They are complex as
they use the environment that they are attached to develop channels that allow for the
maintenance of the bacteria that are within the biofilm.[29,30] As such, they are harder to be
eradicated compared to planktonic bacterial cells. Due to the ability of bacteria to bind
surfaces such as medical devices and sites of infection, there is an urgent need for the
identification of new antimicrobial agents that could inhibit the growth of bacterial biofilms.
We thus evaluated the lead compound C16-K-RBB2 for its ability to decrease biofilm
formation. Intriguingly, this compound was able to significantly reduce biofilm formation in
both Gram-negative E. Coli (Figure 5A) and Gram-positive MRSA (Figure 5B) bacteria.
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The results further strength the potential of lipidated α/α-AA peptide hybrid as a new class
of antimicrobial agents.

3. EXPERIMENTAL PROCEDURE
3.1. General Information

Author Manuscript

Sequences were synthesized using solid phase synthesis. To do this Rink amide MBHA resin
(100–200 mesh, 0.64 mmol/g) from Chem-Impex International, Inc was used. The α-AA
peptides were synthesized by using a peptide reaction vessel clamped on a Burrell WristAction Shaker and purified using High performance liquid chromatography (HPLC)
equipped with a preparative C18 column (5μm, 9 × 250 mm). The molecular weight of the
desired fraction was confirmed using MALDI-TOF (Bruker AutoFlex) mass spectrometer,
and the product was dried on a labcono lyophilizer. All other chemicals were purchased for
either Sigma Aldrich or Fischer unless otherwise stated.
3.2. Solid Phase Synthesis
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[24] The solid phase peptide synthesis was conducted by using 100 mg of Rink amide
MBHA resin in a peptide reaction vessel on a shaker. The resin was first treated with 20%
piperidine in DMF for 15 min to remove Fmoc group. This step was repeated twice and after
each time the beads were washed with 3 mL DMF and DCM alternatively. Subsequently, αAA build block (2 equiv.), HOBT (6 euiv.) and DIC (6 equiv.) were dissolved in DMF and
shaken for 10 min, and the mixture was added to the vessel and left to shake overnight. The
beads were washed with DMF and DCM. After Fmoc group was removed, either one more
α-AA building block, or the lysine amino acid, or a lipid tail, was coupled onto the beads,
respectively depending on the sequences to be synthesized. The synthetic cycle was
continued until the desired sequence was completed. The sequence was then cleaved from
the beads using a 1:1 ratio of TFA: DCM for two hours. The solution was collected, dried
over the air, and the residue was dissolved in water, which was subsequently purified by
HPLC.
3.3. Minimum Inhibition Concentration (MIC) – Antimicrobial Assay: [22]
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MIC is used to determine the minimum compound needed to inhibit both Gram-positive and
Gram-negative bacteria. In the case of this experiment Escherichia coli (E. coli, JM109), and
Klebsiella pneumoniae (K. pneumoniae, ATCC 13383) were used as the Gram-negative
specimen, while Methicillin Resistant Staphylococcus aureus (MRSA, ATCC 33591),
Methicillin Resistant Staphylococcus epidermidis (MRSE, RP62A), and Vancomycin
Resistant Enterococcus faecalis (E. faecalis, ATCC 700802) were used as the Gram-positive
specimen. To test the inhibition properties, one colony of bacteria was first taken from an
agar plate and grown overnight in trypicase soy broth (TBS) media at 37 °C on a shaker.
Subsequently, one colony was taken again and allowed to grow to mid-logarithm phase. Of
this, 50 μL of 106 CFU/mL bacteria was added to each well of a 96 well plate along with
50μL of diluted lipidated α/α-AApeptides (100 to 0.5 μg/mL). After 18 hours of incubation
at 37°C the MIC was determined by using a Biotek microplate reader with optical density of
600 nm. The lowest concentration of peptides to inhibit bacterial growth was considered as
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the MIC. All experiments were done three times, each time being duplicates. The control
was the bacteria not treated with any peptides.
3.4. Hemolytic Studies: [26]
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Freshly obtained human red blood cells were used for measurement of hemolytic activity of
compounds. The cells were washed a few times with phosphate buffered saline (PBS) and
centrifuged at 1000g for 10 minutes. The supernatant was then discarded and the red blood
cells were resuspended in PBS to obtain a 5% volume by volume concentration. A 96 well
plate was then used to contain a two-fold dilution of C16-K-RBB2 to make a total of 50μL in
each well. To which 50μL of 5% volume by volume of red blood cells solution was added.
The plate was then stored at for 1 hour at 37 °C and centrifuged for 10 minutes at 3500 rpm.
The supernatant was collected and diluted with 100 μL of PBS to detect the hemoglobin
using a Biotek microtiter plate reader (Synergy HT) at 540 nm. Controls were used to
determine 0% hemolysis by incubation in PBS and 100% hemolysis by treatment with 0.1%
Triton-X-100 in PBS. The percent hemolysis was determined by using the formula:
% Hemolysis = (Abssample − AbsPBS)/(AbsTriton − AbsPBS) × 100

3.5. Fluorescence Microscopy: [25]
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The double dyes staining method, using 4′,6 diamidino-2-phenylindole dihydrochloride
(DAPI, Sigma, >98%) and propidium iodide (PI, Sigma), was employed to assess bacterial
membrane integrity. DAPI is a cell permeable dye and has a great ability to bind to the A-T
rich regions of double stranded DNA which allows for very strong fluorescence.[28] PI on
the other hand is an ethidium derivative that are able to penetrate the cell walls of dead cells
but not living cells. Therefore combination of both DAPI and PI were used to quantify the
bacterial cells that became necrotic due to treatment with C16-K-RBB2.[27] These stains
were used to determine the viability of both E. coli and MRSA. The bacterial cells were
cultured to the mid-logarithmic phase, and then incubated for 4 h at 37 °C with C16-KRBB2 (5 μg/mL). They were then centrifuged at 3000g for 15 minutes and the supernatant
was removed. The pellets that were collected were washed with PBS then incubated with
DAPI (10 μg/mL) for 15 minutes at 0°C in the dark. After 15 minutes the excess DAPI was
washed a few times with 1 × PBS. The pellets were also treated with PI (5 μg/mL) and
incubated at 0°C in the dark for 15 minutes, after which the excess PI was washed off with 1
× PBS. The controls were tested using the same method stated above, however, the cells
were not incubated with C16-K-RBB2. The cells were then observed using a Zeiss Axio
Imager Z1 optical microscope (100×).
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3.6. Time Kill Studies: [26]
This assay was done in triplicates to determine the kinetics of the peptide C16-K-RBB1 as it
relates to termination of bacteria. To determine this, the bacteria were incubated at 0, 10, 20,
30,60 and 120 minutes with various concentrations of the peptide. 100 μL of bacterial
suspension was then taken from each time interval and further diluted. The diluted
suspensions were incubated at 37°C on agar plates for 20 hours and the colonies counted.
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3.7. Biofilm Assay:6
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This assay was done in duplicates to determine the prevention of biofilm growth. MRSA and
E. coli, were grown to 1X106 CFU/mL in a 96 well plate containing 50μL trypticase soy
media, and 2:1 serial dilution of tested compound in 50μL of PBS. The plate was then
incubated at 37°C for 24 hours and then 10 μL of crystal violet stain was added to each well
at a concentration of 0.5% weight by volume. The plates were then washed with TBS to get
rid of any cells that did not stick to the plate and 95% ethanol was added to the plates so as
to dissolve the stain. A microtiter plate reader was then used to determine the formation of
biofilm by taking readings at a wave length of 600 nm. The lesser the optical density at
600nm is equivalent to a decrease in biofilm formation.

4. CONCLUSION
Author Manuscript

In summary, we have developed a new class of lipidated α/α-AA heterogeneous peptides.
They show excellent activity against both Gram-positive and Gram-negative bacteria,
including clinically relevant bacterial strains. Our structure activity relationship studies
suggest that lipidation, hydrophobicity, and positive charge, as well as their spatial
arrangement, are of importance to selectively target bacterial cells over mammalian cells.
Furthermore, our mechanistic studies show that the compounds could mimic HDPS and are
capable of eradicating both Gram-positive and Gram-negative bacteria in a timely manner,
while also eliminating the formation of biofilms. Therefore, lipidated α/α-AA
heterogeneous peptides could be a new generation of antibiotic agents with potential
therapeutic applications.
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HIGHLIGHTS
•

Design and synthesis of 13 lipidated α/α-AA heterogenous peptides as
mimics for Host Defense Peptides.

•

Compounds can efficiently kill both Gram-positive and Gram-negative
bacteria and clear bacterial biofilm formation.

•

Compounds have the ability to select for bacterial cells over human red blood
cells.
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Figure 1.

General structure of an α-peptide, an α-AApeptide, and an α/α-AA heterogeneous peptide.
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Figure 2.

Structures of sequences synthesized in Scheme 1, with varying lengths of hydrocarbon tail.
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Figure 3.
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Fluorescence Microscopy of bacterial cells treated with C16-K-RBB2 for 2h (Scale bar
10μm). (1a) Control, DAPI stained, no treatment with compound. (1b) Control, PI stained,
no treatment with compound. (2a) MRSA, DAPI stained, treated with compound. (2b)
MRSA, PI stained, treated with compound. (3a) Control, DAPI stained, no treatment with
compound. (3b) Control, PI stained, no treatment with compound. (4a) E. coli, DAPI
stained, treated with compound. (4b) E. coli, PI stained, treated with compound.
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Figure 4.

Time Kill Assay for Gram-negative E. coli (A) and MRSA (B).
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Figure 5.

Biofilm prevention assay for cells treated with C16-K-RBB2. Error bars based on standard
deviation. E. coli (A) and MRSA (B).
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Scheme 1.

Reaction scheme for solid phase synthesis of lipidated α/α-AA peptide hybrids.
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Scheme 2.

Reaction Scheme for solid phase synthesis of the reverse antimicrobial sequences.
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The antimicrobial activity and selectivity of α/α-AA peptide hybrid shown in Figure 2. “----” indicates the activity was not tested.
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The antimicrobial activity and selectivity of α/α-AA peptide hybrid shown in Scheme 2.
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